10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

ERBB2 Antibody (Center T701) Blocking Peptide

Synthetic peptide
Catalog # BP19589c

Specification

ERBB2 Antibody (Center T701) Blocking Peptide - Product Information

ERBB2 Antibody (Center T701) Blocking Peptide - Additional Information

Format
Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions
This product is for research use only. Not for use in diagnostic or therapeutic procedures.

ERBB2 Antibody (Center T701) Blocking Peptide - Protein Information

ERBB2 Antibody (Center T701) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Blocking Peptides

ERBB2 Antibody (Center T701) Blocking Peptide - Images

ERBB2 Antibody (Center T701) Blocking Peptide - Background

This gene encodes a member of the epidermal growth factor(EGF) receptor family of receptor tyrosine kinases. This proteinhas no ligand binding domain of its own and therefore cannot bindgrowth factors. However, it does bind tightly to other ligand-boundEGF receptor family members to form a heterodimer, stabilizingligand binding and enhancing kinase-mediated activation ofdownstream signalling pathways, such as those involvingmitogen-activated protein kinase and phosphatidylinositol-3 kinase.Allelic variations at amino acid positions 654 and 655 of isoform a(positions 624 and 625 of isoform b) have been reported, with themost common allele, Ile654/Ile655, shown here. Amplification and/oroverexpression of this gene has been reported in numerous cancers,including breast and ovarian tumors. Alternative splicing resultsin several additional transcript variants, some encoding differentisoforms and others that have not been fully characterized.

ERBB2 Antibody (Center T701) Blocking Peptide - References

Geradts, J., et al. Cancer Invest. 28(9):969-977(2010)Zaoui, K., et al. Proc. Natl. Acad. Sci. U.S.A. 107(43):18517-18522(2010)Oliveras, G., et al. Ann. N. Y. Acad. Sci. 1210, 86-92 (2010) :Han, J.S., et

al. Anticancer Res. 30(9):3407-3412(2010)Stackievicz, R., et al. Isr. Med. Assoc. J. 12(5):290-295(2010)